Moffitt Cancer Center 2008 Annual Report
The Pace Of Innovation Intensifies…
Transform Discoveries Into
Moffitt Cancer Center 2008 Annual Report
2008 Year-In-Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Lung Cancer SPORE Grant . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Health Disparities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1
Total Cancer Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Moffitt In The Community. . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Financial Highlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Leadership Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Miles For Moffitt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
ABOVE Tonya Brooks, left, rejoices with Tamara Clarke, medical assistant in the GI Oncology Clinic.
Brooks had been diagnosed with an endocrine tumor in April 2007. She underwent many radiation
treatments and cycles of chemotherapy. A participant in the Total Cancer Care protocol, Brooks says
she got a “clear scan” the day this photo was taken.
ON THE COVER Gerold Bepler, M.D., Ph.D. (foreground), holds a tissue microarray slide used in
lung cancer research, while his colleague Eric Haura, M.D., meets with cancer survivor Julie Ingram.
PHOTOGRAPHY BY DICK DICKINSON
At Moffitt the commitment
to remaining on the
This time of Moffitt CEO
growth at Moffitt and Center Director cutting-edge of discovery
Cancer Center is an William S. Dalton,
exciting one, and I Ph.D., M.D., was
am honored to serve invited by the U.S.
as incoming chair of Department of Health and Human Services Secretary
Moffitt’s Board of Michael O. Leavitt to present at the National Summit on
Directors. Personalized Health Care held in Utah during November
Sen. Connie Mack, 2008. There Dr. Dalton presented on “Community-Based
the immediate past Personalized Health Care” that defined personalized
chairman, will remain cancer care through Moffitt’s Total Cancer Care Program
on the Board as chair and described progress to date and future plans.
Robert Rothman, Chairman
emeritus and continue Dr. Dalton joined
to be actively involved several other leading
at the Cancer Center. Sen. Mack accomplished much medical institutions
during his seven-year tenure as chairman, including and their partners who
Moffitt designation as a National Cancer Institute (NCI) contributed reports
Comprehensive Cancer Center in 2001, the opening of of activities and plans
the Vincent A. Stabile Research Building, and expansion toward different
of the Moffitt Clinic. Under his leadership, the Cancer aspects of personal-
Center received its largest single gift of $20.4 million ized health care.
from Donald A. Adam to develop the Comprehensive Disparities in
Melanoma Research Center (CMRC). One of Sen. Mack’s health care is a serious
next endeavors will be to establish additional advisory issue in the Tampa
resources for the CMRC. Bay area and beyond.
At Moffitt the commitment to remain on the cutting- Moffitt is committed
edge of discovery remains constant. The NCI awarded to reducing disparities
Gerold Bepler, M.D., Ph.D., and his team a Specialized and working toward Community outreach and education
Programs of Research Excellence (SPORE) grant in lung closing gaps in health help reduce health disparities.
cancer, totaling $10 million over five years. This grant care outcomes.
focuses on translational research in a specific disease Community outreach and other efforts leading to
and is among the largest NCI awards. You can read progress toward these goals are described in this report.
more about the SPORE grant award — a first for Moffitt — Moffitt is one of the first cancer centers in the country
in this annual report. to embrace the concept of patient- and family-centered
care by developing a formal program to
...Cancer Center physicians and scientists are advance the practice. Patients, family
members, physicians and Moffitt staff are
developing a personalized approach to cancer care working side by side to address issues
through Moffitt’s Total Cancer Care Program. ™ related to the patient experience. For
example, Moffitt’s Patient and Family
Advisory Council members are actively
In a continuing effort to translate basic science working on an online Patient Portal. In addition to allow-
discoveries into better treatments, Cancer Center ing patients to schedule their appointments online, the
physicians and scientists are developing a personalized Patient Portal will offer cancer survivors access to a
approach to cancer care through Moffitt’s Total Cancer summary of their treatment as well as a personalized
Care™ Program. In this report you can learn about a study survivorship care plan. Cancer survival is associated with
that for the first time enrolls patients with ovarian cancer extensive and unique psychosocial and medical needs.
who will receive a chemotherapy regimen based on the The right surveillance and follow-up testing and monitor-
genetics of their specific cancer. Moffitt Cancer Center is ing for unrelated diseases are important factors and can
among the pioneers of this cutting-edge initiative that be complex. For these reasons, Moffitt is developing a
combines information technology, scientific discoveries, Survivorship Clinic, scheduled to open in early 2009.
and clinical care to deliver cancer treatment that is The Patient Portal and the Survivorship Clinic will be
personalized, based on each patient’s genetic makeup. fully integrated into Moffitt’s Total Cancer Care Program.
Moffitt Cancer Center 2008 Annual Report
We continue to look for ■ Anna Giuliano, Ph.D., has pioneered research leading to
opportunities to collaborate in the licensure of GARDASIL, a vaccine against human
cancer-related research efforts, papillomavirus (HPV) which is known to cause cervical
and last year Moffitt, Shands cancer in women. She has received several NIH-funded
HealthCare and the University of grants related to the understanding of the natural
Florida announced a partnership history of HPV infections in both men and women.
in which they will work together She is the lead author
to develop world-class programs of a study published
An aerial view in cancer care, research and in the August 19,
of Moffitt Cancer
Center shows prevention. The partnership is expected to enhance 2008, issue of the
expansion to Florida’s reputation in cancer care and research, ulti- prestigious journal
mately contributing to the improvement of the standard Vaccine, which
of cancer care in Florida and beyond. Moffitt’s Total described the
Cancer Care model will be integrated with the cancer epidemiology of HPV
program at Shands at the University of Florida. infection in men and
Moffitt maintains its strong relationship with the its impact on HPV-
University of South Florida (USF), having signed a new related disease in
partnership agreement for its affiliation, which has been men and women.
designed to maximize focus and flexibility. A newly created Dr. Giuliano, lead
USF Department of Oncologic Sciences provides the investigator of the
academic home for faculty physicians and scientists who male vaccine efficacy trial, recently represented Moffitt
work at Moffitt Cancer Center. And a newly formed Moffitt by presenting data illustrating that GARDASIL prevents
Medical Group (MMG) became a subsidiary corporation infection and disease in men at EUROGIN (European
of the H. Lee Moffitt Cancer Center & Research Institute. Research Organization on Genital Infection and
Moffitt faculty and staff are committed to putting Neoplasia) 2008 held in Nice, France.
an end to cancer, as highlighted in some of the many
■ Reflecting Moffitt’s commitment to prepare the next
accomplishments for the year.
generation of cancer leaders as part of the Cancer
■ Grant support increased from 536 grants in fiscal Center’s mission, Julie Djeu, Ph.D., and her team were
year 2007 to the fiscal year 2008 figure of 582, of awarded a training grant by NCI to develop a Tumor
which 188 grants were peer-reviewed. Grant funding Immunology Training Program. The program will train
increased from $58.4 million in 2007 to $59.7 million postdoctoral fellows to enter the field of translational
in 2008, of which $45.7 million were funds from immunology and immunotherapy.
■ Dmitry Gabrilovich, M.D., Ph.D., was appointed section
■ The National Institute of Allergy and Infectious head of Dendritic Cell Biology within the Immunology
Diseases of the National Institutes of Health Department. Dr. Gabrilovich is conducting research on
awarded a $2,079,548 grant, “Recommendation many fronts, such as studying abnormalities in function
of HPV [human papillomavirus] Vaccination of dendritic cells, understanding mechanisms of tumor-
Among U.S. Physicians.” Principal investigator associated immunosuppression and developing new,
Susan Vadaparampil, Ph.D., M.P.H., is leading a effective cancer vaccines and aspects of immature
team of investigators from Moffitt, USF Health, myeloid cell biology.
Johns Hopkins Bloomberg School of Public Health,
■ Moffitt received the CEO Cancer
and Cincinnati Children’s Hospital Medical Center to
Gold Standard™ accreditation,
study influences on recommendations of vaccination
recognizing its commitment to
in the years following licensure of the HPV vaccine
the health of employees and
GARDASIL. The vaccine protects against the types
their families, joining 21 other
of HPV that cause 70 percent of cervical cancers.
organizations across the country
The study will continue through June 30, 2012.
that met a high standard for
■ For the tenth year in a row Moffitt Cancer Center appeared cancer prevention, screening and
on U.S. News & World Report’s list of “America’s Best care guidelines. The Cancer Center is the only
Hospitals” for cancer, ranking number 16. organization in Florida to receive this distinction.
■ Collaborating with its affiliate, the Ponce School of
Medicine, Moffitt Cancer Center sent faculty and staff
to Ponce, Puerto Rico, to help conduct a day-long
cancer education event presented entirely in Spanish.
The outreach effort included investigators from both
Moffitt and Ponce, in addition to local physicians from
Ponce. The two institutions are developing cancer
education, training and outreach opportunities for the
Puerto Rican community. They also are collaborating
on basic research projects and working together to
secure tissue samples that will help researchers in their
search for better cancer treatments as part of an NCI
grant-funded minority institution/Cancer Center
Moffitt is the only cancer center ever to be featured on
the Working Mother magazine list of 100 Best Companies. partnership program.
■ For the first time, Moffitt ranked on Working Mother
magazine’s list of “100 Best Companies To Work For.”
The Cancer Center was selected because of the
creative and proactive ways it helps employees meet
the challenges of balancing work and family. In another
first, the Oncology Nursing Certification Corporation
has honored Moffitt as one of the best places for
oncology nurses to work.
■ Moffitt Cancer Center’s campus became 100 percent
tobacco-free, with no smoking or tobacco use allowed
anywhere on Moffitt property. The Cancer Center
provides free hotline numbers for tobacco cessation
M2Gen construction progress.
program resources and smoking cessation classes.
■ Moffitt established a new Department of Integrative
Mathematical Oncology (IMO) that will integrate ■ As last year’s annual report was going to press, M2Gen
computational modeling tools into clinical and experi- broke ground. The building that will house M2Gen,
mental cancer research. By using a range of mathemat- Moffitt’s wholly owned subsidiary, is expected to be
ical/computational modeling approaches targeted completed by early 2009. The construction is taking
at specific types of cancer, investigators will be able place off McKinley Drive, a few miles from the Cancer
to use these models in aiding the development and Center’s main campus. Upon completion, the size of
testing of cancer treatment strategies. The Cancer Moffitt’s campus is expected to double. In collaboration
Center recruited several key members who are with Merck & Co., Inc., M2Gen aims to expand efforts
heavily involved in the formation of the IMO initiative. in research and biotechnology.
Robert Gatenby, M.D., is chair, Integrative Mathematical
As you can see, Moffitt Cancer Center experienced
Oncology; Alexander “Sandy” Anderson, Ph.D., is
growth on all fronts during the past year. I look forward
co-director of the Department of IMO; and Robert
to the upcoming year in expectation of even greater
Gillies, Ph.D., is vice chair, Research, and director,
achievements that will take place at Moffitt Cancer
Molecular and Functional Imaging.
Center. My thanks to all of you who are helping to make
■ Offering the next evolution in surgery, the Cancer this possible — faculty, staff, donors, and especially the
Center added a da Vinci® Surgical System, which patients and their loved ones. The future holds great
allows surgeons to perform minimally invasive robotic promise as we work together in the fight against cancer.
surgeries in the Genitourinary and Gynecologic Oncology
Programs. By enhancing surgical capabilities, the
system helps improve clinical outcomes and redefine Robert Rothman
standards of care. Chairman
Moffitt Cancer Center 2008 Annual Report
New SPORE Grant Reinforces
Efforts To Stop Lung Cancer
In September, researchers in the Thoracic Oncology Program
at Moffitt Cancer Center gained a new advantage in their quest
to prevent and cure lung cancer. Progress toward a cure for lung
cancer, which is responsible for nearly one third of all cancer deaths
in the United States, has been slow. However, with the award of the
National Cancer Institute’s Specialized Programs of Research Excellence
(SPORE) grant, totaling $10,475,090 over five years, significant research is being
ramped up, and Moffitt’s team of researchers is even more confident about their ability
to put an end to cancer.
“This grant acknowledges the continuing translational work being carried out by the
laboratory and clinical team members in our Thoracic Oncology Program,” says Gerold
Bepler, M.D., Ph.D., program leader, Thoracic Oncology. “Getting the SPORE grant means
that a national panel of cancer experts at the NCI [National Cancer Institute] recognize
the quality of our work and the depth of our dedication. SPORE puts us in the company
of institutions such as the M.D. Anderson Cancer Center, the Mayo Clinic and the Johns
Hopkins Hospital, but most importantly, it gives us the tools we need to fight
this leading cause of death for men and women.”
SPORE grants are funded through specialized center grants that The RRM1 gene,
promote interdisciplinary research and help move basic research findings depicted in the
yellow and green
from the laboratory to clinical settings, involving cancer patients sections above,
and populations at risk of cancer. plays a key role
in lung cancer.
Interdisciplinary Programs Apply
Translational Research Approach
Moffitt Cancer Center’s Thoracic Oncology
Program includes a group of physicians who have
expertise in diagnosing and treating lung cancer.
Specialties in the program include medical
oncology, pulmonology, surgery, pathology,
radiation therapy and radiology.
Patient care, clinical research,
education and cancer control activities
at Moffitt are integrated into all the
Cancer Center’s interdisciplinary
clinical programs, including the
Thoracic Oncology Program,
and are organized into disease-
oriented programs. These clinical
programs focus on breast, gastroin-
testinal oncology, gynecologic
oncology, neuro-oncology, and
more. The full listing can be found
on Moffitt’s Web site, MOFFITT.org,
under “clinical programs” within
the “patient information” section.
The specialists in these programs work
together to ensure coordinated patient care
and an aggressive approach to treatment.
In a continuing effort to provide personalized
cancer care, researchers at Moffitt are moving their basic
science discoveries from the laboratory into the clinic by
way of investigator-initiated clinical trials. These efforts
ultimately are translated into lifesaving treatments that
can be delivered to the patients who need them.
Gerold Bepler, M.D., Ph.D.
Physician-Scientists Aim To Reduce research projects: the impact of E2F (a factor that turns
genes on and off) on therapeutic efficacy of cancer
Lung Cancer Incidence And Mortality treatment; the antitumor mechanism of Src inhibitors;
According to Dr. Bepler, Florida is second behind lung cancer chemoprevention with enzastaurin; and a
California in new cases of lung cancer annually. He hopes p53-based vaccine for small cell lung cancer.
that the kind of interdisciplinary work by specialists in the Interdisciplinary SPORE research teams already at
Thoracic Oncology Program with major support from the work at Moffitt have been actively working with other
SPORE grant will help slow that trend. SPORE teams through collaborations with other National
“Our laboratory and clinical scientists share a common Institutes of Health programs, both nationally and inter-
goal — to bring new ideas to clinical care that can reduce nationally.
incidence and mortality as well as improve quality of life Several research initiatives funded under the SPORE
and survival rates,” says Dr. Bepler. grant are already underway. For example, Dr. Bepler’s
The prestigious NCI SPORE grant provides Moffitt research interests include investigating the molecular
physician-scientists the resources to conduct four key changes that lead to the development of lung cancer
and identifying the molecular targets that play a role
in disease progression.
Research identifying molecular targets is based
on the concept of developing “personalized medicine.”
Personalized medicine takes into account the genetic
makeup of tumors and seeks to “fit” treatment with the
genetic “expression” of individual tumors to optimize
ABOVE LEFT Kenneth Johnston, R.N. (left),
with lung cancer survivor Julie Ingram.
ABOVE Douglas Cress, Ph.D. (left), and
Jiandong Chen, Ph.D., are investigating a
cellular pathway that may be important to
lung cancer treatment.
Moffitt Cancer Center 2008 Annual Report
therapy and tailor each patient’s treatment regimen. “Gemcitabine’s effi-
Current lung cancer SPORE research also is aimed at cacy in chemotherapy is
enhancing treatment based on the concept of “personal- thought to be related to
ized medicine,” a genetic approach to diagnosis and proteins involved in the
treatment that takes into account variations in patient activation, metabolism
genetics, tumor genetics, or both. and transport of the
drug,” says Dr. Bepler, Yihong Ma, M.D., Ph.D.,
RRM1 Tumor Gene Expression who has been investigating research scientist
Corresponds To Treatment Response the RRM1 gene’s potential
as a tumor suppressor for some time. “Our work demon-
Dr. Bepler and associates have found that a tumor strates that RRM1 is a major cellular determinate of the
gene called RRM1 is the molecular target for the cytotoxic efficacy of gemcitabine.”
chemotherapy agent gemcitabine and can predict the What their findings mean for patients with non-small
effectiveness of this drug. When targeted by gemcitabine, cell lung cancer (NSCLC) is that their physicians will be
RRM1 increases its expression and influences how the better able to assess which chemotherapy agents have
tumor reacts to chemotherapy. The reaction allows the most impact on tumor genetic makeup and on the
physicians to predict the chemotherapy’s impact on progression of disease.
Personalized Medicine And The Personal Touch
Joan Tashbar, 65, didn’t like her poor prognosis or the cool way it was
delivered after she was diagnosed with non-small cell lung cancer in
2004. Suspecting there was a better way, a better place and a better
system for her treatment, she became proactive.
“I read the newspaper front to back,” says
the Orlando resident. “I saw there was an
oncology conference scheduled here in
Orlando where state-of-the-art care for
cancer was being discussed. There was also
a public forum, so I went.” There Moffitt’s
Dr. Bepler presented on current research and
clinical trials at Moffitt after which she intro-
duced herself and described her diagnosis
Joan Tashbar “I was pretty amazed,” says the mother of
two and grandmother of five. “Dr. Bepler took
out his cell phone and called his assistant. He set up an appointment for
me right then and there.”
At Moffitt she quickly underwent scans and evaluation. Her tumor
was deemed inoperable.
“‘It’s not the end of the road,’ that’s what Dr. Bepler told me,” Tashbar
recalls. “After what I had heard from other doctors, I was really happy
to hear that!”
After eight weeks of undergoing
treatment with gemcitabine-contain-
ing chemotherapy concurrent with
radiation, she was back at work as a
retail manager. As she marks the five-
year anniversary of her diagnosis in
2009, she will require a checkup at
Moffitt only once yearly.
“For me, meeting Dr. Bepler at
that conference was a lifesaver,”
Tingan Chen, M.D., Ph.D.,
Genetic Makeup Holds Key SPORE Research Projects Bring
To Personalized Treatment Cures One Step Closer
The aim of personalized medicine is to get patients Also with funding from SPORE, molecular oncolo-
like Tashbar on the right drug by taking advantage of gists Douglas Cress, Ph.D., and Jiandong Chen, Ph.D.,
recent scientific breakthroughs that make it possible for are examining a specific cellular pathway that limits
researchers to determine individual tumor gene expression the efficacy of standard chemotherapeutic drugs in
“signatures.” This signature, like a “fingerprint” of the treating NSCLC.
tumor’s genetic makeup, is used to predict an individual “The drugs used in the treatment of lung cancer
patient’s response to cancer therapy. could be more effective if lung cancer cells did not
Just as patients have differing traits, one patient’s have built-in mechanisms that allow them to resist the
tumor may be different from another’s, and Moffitt drugs,” explains Dr. Cress. “Our research is providing
researchers now know that people with the same us with a new way to counteract these
cancers may not respond to the same drug or respond built-in mechanisms.”
Just as patients have
in the same way. With the latest technology, Moffitt According to Dr. Cress, the effective-
researchers can test a single tumor for approximately ness of drugs meant to kill cancer cells is differing traits, one
30,000 individual genes. impeded by a physiological pathway involv-
patient’s tumor may be
ing E2F1 and SirT1. When drugs
are effective, E2F1 is induced by different from another’s,
anticancer drugs and promotes
and Moffitt researchers
the death of non-small cell
lung cancer cells. However, the now know that people
researchers have identified a
with the same cancers
tor” called SirT1 may not respond to the
same drug or respond
E2F1, limiting the
effectiveness of in the same way.
sis is that the E2F1 pathway
is crucial for the effectiveness
of chemotherapy drugs,” says
Dr. Cress. “Targeting that path-
way should have a therapeutic
In another SPORE research
program, thoracic oncologist
Eric Haura, M.D., and scientists
Jin Cheng, Ph.D., M.D., and
W.J. Pledger, Ph.D., are examin-
ing Src proteins that may play
a regulatory role in cancer cell
growth. The research team
Jin Cheng, Ph.D., hopes to identify biomarkers
M.D. (left), and
Eric Haura, M.D.,
and evaluate the effect of Src inhibition on
are examining tumor growth.
may be involved
“Regulation of key pathways allows Src
in the growth of to control cellular growth and proliferation,
survival, invasion and angiogenesis,” explains
Dr. Haura, who adds that there is “known
cooperation between EGFR and Src proteins.”
Moffitt Cancer Center 2008 Annual Report SPORE GRANT
Lung Cancer Chemoprevention
receptor) is acti-
vated by certain Chemoprevention is the use of specific drugs to
proteins. reverse, suppress or prevent the process by which normal
Immunologists cells are transformed into cancer cells, a process called
Dmitry Gabrilovich, “carcinogenesis.” An investigational drug called enzas-
M.D., Ph.D., and taurin is being tested at Moffitt for its ability to prevent
Scott Antonia, lung cancer, especially for people who are former
Tissue M.D., Ph.D., smokers. The hope is that enzastaurin can prevent
are used program leader, Immunology, and medical director, or reduce the growth of cells in the lungs that may
to analyze Cellular Therapeutics Core, will be able to continue their become cancerous.
of tumor work on a p53 vaccine for small cell lung cancer (SCLC) “The focus of lung cancer chemoprevention is on the
tissue. through SPORE grant funding. inhibitors of what are called inflammatory response path-
“SCLC is frequently associated with mutations in ways and the growth factor signaling pathways in cells,”
the p53 gene,” explains Dr. Gabrilovich. “Because tumor says molecular oncologist Mark Alexandrow, Ph.D., who is
cells rely on abnormal p53 for their survival, targeting working with Dr. Bepler on the chemoprevention SPORE
p53 with a vaccine holds promise for producing a clinical project. “We are testing enzastaurin in former smokers to
response.” see if it will reduce the proliferation of bronchoepithelial
It’s estimated that up to 90 percent of patients cells present in precancerous lesions that are defined
with SCLC have the p53 defect. Drs. Gabrilovich and as metaplastic or dysplastic.”
Antonia are conducting clinical trials to determine if a According to Dr. Alexandrow, these are the cells
p53 vaccine, developed from the patients’ own white that can potentially transform into cancer cells when
blood cells, will help the immune response of patients those cells — affected by smoking or other factors —
with the p53 gene defect who are also receiving are triggered into uncontrolled growth by inflammation
chemotherapy. They expect that when the vaccine is and growth factor signaling. The hope is that oral treat-
followed by chemotherapy, the clinical response will be ment with enzastaurin will have a suppressive effect on
greater. In earlier trials the vaccine was found to be safe the cells that may be precursors to cancer cells, thereby
and produced major tumor responses. preventing carcinogenesis.
Thinh V. Cao, B.S.
(left), and Mark
whether the drug
Barriers To Health Care:
ELIMINATING THE DISPARITIES
For Americans, access to health care historically has the health care delivered at Moffitt is delivered equally.
been — and often remains — unequal. Disparities exist in In early 2009 the name of the Office of Institutional
terms of who gets care and when it’s received, the quality Diversity is changing to Moffitt Diversity.
of care delivered and the outcomes of treatment. Many “Health care disparities have an impact on the health
factors feed into health care disparities, such as language care system, on the economy and on people’s lives,” says
barriers, economic realities and an individual’s education B. Lee Green, Ph.D., vice president
regarding health, disease and illness. And some forms of of Moffitt Diversity. “We should
“Health care disparities
cancer are more prevalent in some social classes and strive for equality in health care
ethnic groups. regardless of race, ethnicity, have an impact on the health
Not content to merely recognize disparities in health income or geographic location.”
care system, on the economy
care and outcomes as social facts of life, Moffitt Cancer Of course, cancer, like many
Center administrators, physicians and researchers are other diseases, is not an “equal and on people’s lives.”
actively engaged in efforts to reduce disparities and, opportunity” disease, and many
where possible, close the gaps in health care outcomes forms of cancer strike minorities disproportionately.
that may exist due to socioeconomic status, genetics For example, African-American men — regardless of their
or social realities based on race and ethnicity.
Moffitt’s Office of Institutional Diversity
is on the “front lines” making efforts to not
only educate the public about disparities and
encourage research to close the gaps when
cancer strikes, but also to help make sure that
Emerson Tillman (left)
with Robert Benn
Barbershop Project Tackles
The “Barbers Against Prostate Cancer”
(BAPC) program is taking awareness into the
community by informing African-American
men about their higher risk for prostate
cancer. Juan Luque, Ph.D., and Brian Rivers,
Ph.D., M.P.H., are co-leaders of this project
that links a key institution in the community
to health information.
“Men who are getting a haircut at partici-
pating barbershops can also get lifesaving
information on their risk for prostate cancer,”
says Moffitt’s Dr. Rivers, who serves as execu-
tive director of the Florida Prostate Cancer
Funded by the National Cancer Institute,
BAPC is a joint project between Moffitt, the
Tampa Bay Community Cancer Network and
the Community Health Advocacy Partnership.
“Most men visit a barbershop, but not
everyone is going to go to a doctor,” says
Emerson Tillman, owner of Tillman’s Barber-
shop in East Tampa.
Dr. Rivers and the non-profit FPCN he
heads have a singular focus — they want to
prevent prostate cancer deaths.
Since its inception, FPCN has screened
more than 10,000 men, says Dr. Rivers. The
FPCN also is active in promoting education,
research and community outreach.
Moffitt Cancer Center 2008 Annual Report
...cancer, like many other
diseases, is not an “equal
socioeconomic status — and many forms of and discrimination,” says Dr. Green. “We try to
develop prostate cancer identify the root causes of disparities, whether
at a higher rate and die cancer strike minorities they are socioeconomic or based on genetics and
at a rate that is more disproportionately. biology or poor health behaviors.”
than twice the rate at According to Dr. Green, health disparities often
which white men transcend race. More often, disparities originate in
develop and die of the same disease. Hispanic women in economics when people who are struggling to make ends
the United States have higher rates of cervical cancer than meet are less likely to have money to spend on health
non-Hispanic white women. Breast cancer is the leading care, especially screening for cancer.
cause of cancer death among Hispanic women. And As with so many things in life, education is key to
African-American women diagnosed with breast cancer success and lack of education is key to failure. In an effort
are less likely than white women to survive five years past to help close some of the educational gaps, Moffitt spon-
diagnosis. Colorectal cancer rates are higher in native sored National Minority Cancer Awareness Week events
Alaskans than in any other group in the United States. this past April. The events focused on cancer prevention,
“In many cases, disparities in mortality are linked to early detection and screening for people in high-risk
late diagnoses. Disparities come in various forms — lack populations.
of insurance, barriers to screening opportunities and care, “At Moffitt Cancer Center, we are unwavering in our
low socioeconomic status, poor health behaviors, racism commitment to embracing diversity in every aspect of
Projects Aim To Reduce
Community outreach and educa-
tion efforts at Moffitt are creating a
partnership with the local community
to develop and improve methods to
reduce cancer disparities. These
objectives are accomplished by:
■ Strengthening commu-
local groups targeting
■ Using and creating
materials that are
culturally and literacy-
■ Providing health educa-
tion links to enhance
Tillman’s Barbershop participates
in Barbers Against Prostate
Cancer. Left to right: Robert Benn,
Emerson Tillman, and Brian
Rivers, Ph.D. Background:
barber Franklyn Radix with
what we do: cancer care, research, education and employ-
ment,” says William S. Dalton, Ph.D., M.D., Moffitt president
“It’s critical that our communities have the best tools
available for making health care decisions,” says Cathy
Tillman shares screening
Grant, M.P.A., Moffitt Diversity director. “That means information with Benn.
education. The more information we have, the better African-American men
face a 60 percent greater
equipped we are to make good decisions.” chance than white men of
getting prostate cancer.
Commitment Is Key
Even when cancer is detected early, there can be
barriers to treatment for minorities and others with a big role in moving our efforts to the next level. “I am
socioeconomic challenges. extremely excited and optimistic about the future of Moffitt
“Our goal is to establish a center that screens for and the impact that our commitment to diversity will have
cancer, assists with issues that may hinder the delivery on our employees, our community and our contribution
of care, and also engages in studies in health disparities to the prevention and
research,” notes Dr. Green. He adds that donors will play cure of cancer.”
Serve Tampa Bay’s
To improve services to members of the
Hispanic community in the Tampa area, Moffitt
Cancer Center conducts educational sympo-
siums in Spanish and also provides simulta-
neous interpretations of certain educational
events into Spanish.
Latinos y el cáncer, encuentro educativo
en Moffitt, a day-long cancer educational event
for the community presented entirely in
Spanish, was first held in 2006. More than 250
participants from the community had access
to short presentations focusing on cancer
prevention, cancer research, and nutrition. The
second Latinos y el cáncer event at Moffitt was
held on November 8, 2008.
Moffitt has twice conducted the educational
symposium, Leukemia, Lymphoma, Myeloma
and Bone Marrow Transplantation: An Educa-
tional Symposium For Patients And Families.
The symposium, with sessions presented in
Spanish or via simultaneous interpretation,
provides information about clinical trials
and hematologic malignancies. The program
encourages participants, particularly under-
represented minorities, to register in the
National Marrow Donor Program, and over
200 people from various backgrounds have
registered to become potential bone marrow
donors through these two events.
Moffitt continues to increase the number
of educational activities at which simultane-
ous interpretations are offered. For example,
in August 2008 a seminar on Nutrition and
Cancer was attended by 65 Spanish-speaking
members of the community. Simultaneous
interpretations into Spanish also have been
available at the FACTors breast conference for
the last two years.
Moffitt Cancer Center 2008 Annual Report
Total Cancer Care (TCC) Delivers Both
TLC (Tender Loving Care) And Science At Its Best
MOFFITT TCC PROGRAM’S GOAL IS because he clearly defines what it means to build on
“PERSONAL MEDICINE” AND DEEP DATA the concept of “personalized medicine” to afford a
better quality of life for the patients and the families
When Timothy Yeatman, of patients who entrust their lives to the many caring
M.D., executive vice president hands at Moffitt.
of Translational Research at “TCC combines information technology, 21st-century
Moffitt Cancer Center, talks science and clinical care that can be ‘personalized’ by
about Total Cancer Care matching the right patient to the right treatment,” says
(TCC), people listen. They Dr. Yeatman. “TCC also includes paying attention to
listen because they sense the quality of life and emotional issues that come with
that TCC is his passion. diagnosis and treatment.”
They also listen because he “Personalized care means that the patient and the
is laying out a prescription patient’s needs are central,” explains Moffitt President
for both good science and and Chief Executive Officer William S. Dalton, Ph.D., M.D.
quality care. And, they listen “It also means identifying genetic and biological markers
Timothy Yeatman, M.D.
Total Cancer Care Brings Benefits
Of Science Closer To The Individual
A wide-ranging initiative, Moffitt Total Cancer
Care, is leading the way for patients to receive
personalized treatment. The global concept of Total
Cancer Care involves delivering state-of-the-art
cancer care to patients throughout Florida and
beyond, combining information technology, science,
and clinical trials in a broad-based mission:
1) Establishing a network of partnerships with
medical center affiliates, community oncolo-
gists, physicians and other health care profes-
sionals to streamline patient access to the
2) Improving patient participation in ongoing
clinical trials aimed at developing improved
health outcomes and patient satisfaction.
3) Developing a database as a source for the
collection, storage, integration, and manage-
ment of clinical data and scientific findings
that can be translated into new treatments.
By combining those data with specific genetic
information, oncologists will be able to tailor
treatments to their patients. Constant compi-
lation and assessment of outcomes will allow
scientists to develop evidence-based treat-
ment guidelines that will be directed back to
oncologists. With each new patient, Moffitt
Total Cancer Care becomes stronger as more
is learned about delivering personalized
TOTAL CANCER CARE
“TCC also includes
to the quality of
that detect cancer, predict Here is how TCC works:
risk or point to the best life and emotional A newly diagnosed patient is enrolled in TCC at
interventions by finding issues that come Moffitt or at a participating treatment center in their
genetic ‘signatures’ that community. Following their biopsy, a frozen tumor sample
could indicate best response with diagnosis is sent to Moffitt where the genetic makeup of the tumor
to treatment. Finally, person- and treatment.” is analyzed. The genetic information is entered into the
alized medicine means using TCC database. During treatment, a patient’s information,
this knowledge to match including a genetic profile of the tumor, is entered into
patients to the right drug or the right clinical trial. It means a secure Web site and constantly updated with imaging
that treatment and caring come in one package.” information and treatment response data. As more infor-
mation is gathered, evidence for what kind of clinical trial
is right for the patient is enhanced. Patients eventually
The Future Of TCC will be able to access their information through an
“The expanding TCC database is going to be robust Internet patient portal now being developed, where they
enough to serve as a tool for clinicians,” predicts Dr. Yeatman. will be able to obtain survivorship care plans. While the
A Key Investment
■ Funding incentives for M2Gen
came from a variety of sources,
including: Hillsborough County
($20 million plus 25 acres
of land); the State of Florida
($15 million); and the City
of Tampa ($800,000 plus
5 acres of land).
■ The economic impact for
M2Gen is significant as the
research initiative generates
new jobs — primarily scientific,
professional and information
■ M2Gen was recognized last
year by the Florida Economic
Development Council as a “Deals
of the Year Award” winner, based
on the outstanding economic
and community potential Moffitt
and Merck, Inc., will bring to
Richard Cay, above, participates
in the TCC protocol. Using an
automated tissue storage
system, research specialist
■ Through M2Gen, Moffitt’s collab-
Celia Sigua, left, can quickly oration with Merck, Inc. brings
access any of the thousands
of tissue specimens that
the highly respected, global
have been profiled by pharmaceutical company to
and are now being
the Tampa Bay region’s list of
stored for future growing economic initiatives.
Moffitt Cancer Center 2008 Annual Report
database serves individual patients and their physi-
cians, it will be extensive enough that new biomarkers
can be identified that can help researchers answer big
outcomes research questions, ultimately leading to
Moffitt adheres to the National Cancer Institute's
Best Practices for Biospecimen Resources report,
released in 2007. This document outlines a collection
of accepted best practices involved in the collection of
biospecimens, management of associated biospecimen
data and provides guidance in matters of obtaining
patient informed consent and responsibilities in safe Andy Nuñez says TCC will
benefit future patients.
guarding protected health care information. All patients
are invited to participate in TCC at Moffitt, where a multi-
while program and will benefit a lot of people
disciplinary committee is responsible for legal and regula-
like me. With so many people contributing their tissue
tory aspects and carefully oversees access to specimens.
samples, we are helping each other and those who will
Patients Learn From The TCC Video Richard Cay, who was visiting Moffitt from his home
Total Cancer Care is a constellation of many moving in Michigan, also signed up to participate in the TCC
parts, and patients learn about it through a video when protocol. For Cay, the good news was that his surgeon,
they first visit Moffitt. Andy Nuñez of St. Petersburg, a Mokenge Malafa, M.D., successfully removed the tumor
patient of William Dinwoodie, M.D., recalled seeing the from his colon as well as a small piece of his liver.
video on a TCC notebook computer. Asked what he thinks about research, Cay, a former
“It was fantastic,” said Nuñez about the technology. medic, stated, “Research is the only way you are going to
“While I was listening I realized that TCC is a very worth- discover cures for different problems, and so I am totally
supportive of research.”
M2Gen Gets Off The Ground
Moffitt TCC Consortium Member Sites A new endeavor at Moffitt, called M2Gen, is expected
As part of Total Cancer Care, Moffitt partners with medical to not only help answer those big research questions,
center affiliates and oncologists throughout Florida and in other but also advance the practice of personalized medicine
states. This network of Moffitt TCC consortium member sites by taking TCC to a new level. M2Gen is a wholly owned
will help improve the quality of cancer care for residents through- subsidiary of the H. Lee Moffitt Cancer Center and
out Florida and beyond, offering patients access to the newest
Research Institute initially established to implement
forms of cancer treatment and participation in clinical trials.
The initiative is unique in its involvement of community oncol- major research collaboration between Moffitt and the
ogists, which is important because more than 80 percent of pharmaceutical company Merck, Inc. The collaboration
cancer cases are treated in the community setting. The follow- is aimed at advancing the science of gene expression
ing are TCC consortium members. profiling and enhancing clinical outcomes.
FLORIDA OTHER STATES “M2Gen will have the potential to develop the
Baptist Health South, Miami Carolinas Medical Center, world’s largest biorepository and database of tumor
Boca Raton Community Charlotte, North Carolina tissue samples,” says Dr. Yeatman, who is M2Gen’s presi-
Hospital, Boca Raton Greenville Hospital System,
dent and chief scientific officer. “M2Gen also will have
Watson Clinic Center for Greenville, South Carolina
Research, Inc., Lakeland Hartford Hospital, Hartford, the potential to connect those patients who donated
Martin Memorial Medical Connecticut tissue samples to the right clinical trials and the optimal
Center, Stuart Our Lady of the Lake treatments that will benefit them.”
Morton Plant Mease Health Regional Medical Center,
Care, Clearwater Baton Rouge, Louisiana
Sarasota Memorial Hospital, St. Vincent Hospital and Biorepository An Essential Key
Sarasota Health Care Center, Parallel to M2Gen and its contribution to personalized
St. Joseph’s Hospital, Tampa Indianapolis, Indiana
medicine and TCC is the ongoing development of a large,
Tallahassee Memorial University of Louisville
HealthCare, Tallahassee Research Foundation, regional cancer biorepository. The databank of tumor
Shands Teaching Hospital Louisville, Kentucky tissue samples, genetic and clinical data will further the
and Clinics, Gainesville Southeast Nebraska Cancer discovery of biomarkers that can be used to identify those
Center, Lincoln, Nebraska at high risk, facilitate early detection, improve prognoses,
TOTAL CANCER CARE
The repository is estimated to
house over three million samples
over the next three years.
allow drug targeting and “This study marks the beginning of the movement
toxicity predictions, and away from ‘one-size-fits-all’ medicine toward true person-
match people to the right alized medicine for patients with ovarian cancer,” says
clinical trials. Dr. Lancaster. “The concept behind matching genetics
Since it was approved to treatment means looking for molecular pathways or
as a protocol in 2006, TCC biomarkers of resistance. Once the ‘Achilles heel’ of the
personalized medicine research tumor is located, we can decide how to switch off that
has enrolled more than 24,000 pathway to improve treatment response rates.”
patients across 16 cancer treatment sites
in Florida and in other states. Consortium “Targeting specific areas of the cancer cell and molecular
sites, identified based on patient volumes and
their ability to gather biospecimens and conduct genetics are the wave of the future, today.”
clinical trials, are helping build the tissue databank.
The biospecimen repository supports advances in According to Dr. Wenham, their study is an example
personalizing treatment through molecular profiling and of a true ‘bench-to-bedside’ approach to finding a cure in
has grown to 8,000 specimens, of which 3,600 have been which bench science discoveries led to innovative clinical
profiled. The repository is estimated to house over three treatments for patients with cancer.
million samples over the next three years. “Targeting specific areas of the cancer cell and molecu-
“When patient clinical data from molecular analysis lar genetics are the wave of the future, today,” he says.
are integrated into management systems, we can better
practice evidence-based medicine,” says Dr. Yeatman. TCC, Outcomes Research
“There are many points along the road to implementing
TCC, and building a warehouse of data is one of the first
And Quality Of Care
steps. With the help of our consortium members, we are TCC also means paying attention to health outcomes,
finding that road is quickly becoming a highway.” says Paul Jacobsen, Ph.D., leader of Moffitt’s Health
Outcomes & Behavior Program. Dr. Jacobsen and
colleague David Shibata, M.D., who serves on the Health
Outcomes Committee, have developed a number of tools
to track the quality of care that patients receive. Most
recently, they developed a “Quality Measurement Protocol
for Colorectal Cancer.” Eight oncologists from three prac-
tice sites participated in a successful pilot project, carrying
out case reviews of 200 patients. This initiative has now
been expanded to include nine affiliate sites.
“The project seeks to examine how doctors adhere to
established treatment guidelines and to establish a way of
measuring quality of care,” explains Dr. Jacobsen. The plan
Jackie Bernabe shows the TCC protocol video
is to create a process by which patient treatment informa-
to Roger Marier, friend of a Moffitt patient. tion can be tracked and evaluated.
“It’s important to find out if patients were offered
Personalized Chemotherapy the opportunity to participate in clinical trials, which
trials they were offered, if they agreed to participate and,
Of the many clinical trials ongoing at Moffitt, a growing if they did not participate, why not,” says Dr. Shibata,
number are clearly rooted in the concept of personalized
medicine and TCC. In one such trial,
Johnathan M. Lancaster, M.D., Ph.D,
director of Moffitt’s Center for Women’s
Oncology, and Robert M. Wenham, M.D., Partnership With Shands And University Of Florida
principal investigator, Total Cancer Numerous partnerships are heightening Moffitt Cancer Center’s commitment to
Care protocol at Moffitt, are conducting develop world-class programs in cancer care, research and prevention. In January
a study that for the first time enrolls 2008 Moffitt, Shands HealthCare and the University of Florida announced such a
patients with ovarian cancer who will partnership in which the institutions work together toward these aims. The collab-
orative effort is expected to enhance Florida’s reputation in cancer care and
have their chemotherapy regimen selected
research, ultimately contributing to the improvement of the standard of cancer
based on the genetic “fingerprint” of care in Florida and beyond. The cancer program at Shands HealthCare at the
their cancer. University of Florida will integrate the Moffitt TCC model.
Moffitt Cancer Center 2008 Annual Report TOTAL CANCER CARE
Total Cancer Care In Action:
Breast Cancer Patient From Pensacola
section head, Colorectal
Surgery in Molecular
Oncology, in Moffitt’s community testing
results Physicians, scientists
Gastrointestinal Oncology Patient Tumor sent added to Clinical info and patients able to
to Moffitt database added by
Program. enrolled community query database
in TCC physician
A second project devel- protocol via Internet
oped by Drs. Jacobsen and evidence-based
Shibata is aimed at providing
patients with a summary of New discoveries
their treatment and a person- patients sooner
alized survivorship care plan.
“We want patients to Multi-
be able to understand and Dimensional
address their ongoing needs Data
as they move from active
treatment to follow-up,”
explains Dr. Shibata.
a critical period, and in the past
a patient might risk getting “lost
“Ongoing scientific research, clinical trials and evidence-based medicine continue
to lay the groundwork for delivering personalized cancer care for each patient.” “In this period patients
can have many questions and
“At Moffitt we aim to develop quality of survivorship concerns about pain, or fatigue or diet,” he adds.
care measures and to help improve the care that cancer “Some may be confused about what they may have to
survivors receive,” says Dr. Jacobsen. “This ties in with do before they see their oncologist again. Our survivor-
the Cancer Center’s Total Cancer Care initiative.” ship program is designed to make sure these people
continue to get a high level of care.”
Survivorship Care Is Focus That high level of care will include a patient portal,
Of New Program a secure Web site where patients can find their personally
developed care plan plus their treatment records.
According to Dr. Jacobsen, a cancer survivor includes Progress is well under way, and a Survivorship Clinic
anyone from diagnosis forward. will soon open its doors.
“However, there is a need for services for that group “We look forward to accepting our first patients in the
of patients who have been diagnosed with early-stage interdisciplinary Survivorship Clinic by early 2009,” says
disease and who have completed surgery and chemother- Richard Gross, M.D., medical director of the Survivorship
apy and are ready for follow-up.” For Dr. Jacobsen this is Program and leader of Moffitt’s Internal and Hospital
Medicine Program. “The program ultimately will be fully
integrated into the Total Cancer Care initiative, opening
unique research opportunities.”
New Partnership Agreement TCC Comes Full Circle
For USF And Moffitt
“It is exciting to see a growing number of cancer
In January 2008, most of the health care providers,
survivors,” says Dr. Dalton. “Their participation in the
including physicians, physicians’ assistants, nurse practi-
tioners and certified nurse anesthetists who practice at Total Cancer Care protocol will be an important compo-
Moffitt and were University of South Florida (USF) employ- nent in the success of finding new and better cures.”
ees officially became employees of the Moffitt Medical In many ways TCC is like a continuing circle, notes
Group (MMG). The newly formed MMG became a subsidiary Dr. Dalton. As each patient is treated and participates
corporation of the H. Lee Moffitt Cancer Center and Research
in TCC, more information is learned about each specific
Institute. The changes mean that the former USF Depart-
ment of Interdisciplinary Oncology has been closed, and type of cancer. The next generation of patients will bene-
the newly created USF Department of Oncologic Sciences fit as more is learned about risk factors, prevention,
provides the academic home for faculty physicians and screening, early diagnosis and the best possible treat-
scientists who work at Moffitt Cancer Center. “The strong ment. “Ongoing scientific research, clinical trials and
relationship with USF will continue, and this change is
evidence-based medicine continue to lay the groundwork
expected to maximize focus and flexibility in practice,”
says Dr. Dalton. for delivering personalized cancer care for each patient.”
MOFFITT IN THE COMMUNITY
Baseball + Skin Cancer Screening = Home Run
Moffitt Cancer Center Moffitt’s Board of Advisors, threw out
and the Tampa Bay Rays hit the ceremonial first pitch. From there,
a home run in March 2008 Spring Swing hit the road in a 40-foot
with the creation of Spring screening bus, which was specially outfitted
Swing™ — Moffitt’s Sun Safety for the tour with a donation from American
Tour. The month-long program Momentum Bank.
provided free skin cancer screen- The bus traveled to Tampa,
ings to fans at nine Major League Fort Myers, Port St. Lucie, “...we have tremendous
Baseball games during the annual rite of spring training. Clearwater, Jupiter,
potential to reduce the
The idea to partner Moffitt with the team came from Dunedin, and Sarasota,
Rays’ principal owner Stuart Sternberg, who serves on and made a return trip to burden of skin cancer
Moffitt’s national Board of St. Petersburg for the Rays’
in the state of Florida.”
Advisors, which is focused last game at Progress
“...Spring Swing was on raising the Cancer Energy Park. Throughout
successful because Center’s awareness in the month, Spring Swing relied on the skills and talents
Florida and throughout of more than 80 volunteers from Moffitt; five affiliate
it saved lives.” the nation. Sternberg had institutions; the Tampa Bay Rays; American Momentum
heard of the Mole Patrol ®, Bank; AAA Auto Club South; Alpha Kappa Alpha Sorority;
Moffitt’s mobile skin cancer screening program, and two Tampa Girl Scout Troops, #1028 and #532; and The
suggested the idea of offering free screenings to fans. Spirit of Kristi.
By month’s end, Spring Swing had screened 695 In May 2007, philanthropist Donald A. Adam, chairman
people in eight Florida cities and found 108 suspected and chief executive officer of American Momentum
skin cancers and 264 suspected precancerous lesions. Bank, donated $20.4 million for the development of a
It also brought a sun safety message to more than Comprehensive Melanoma Research Center at Moffitt.
57,000 fans attending the games and attracted media This center will conduct research in
attention that reached more than 2.1 million television melanoma and translate that into
viewers and 4.8 million online visitors. cutting-edge patient treatment.
“At the most important level, Spring Swing was This represents the largest single
successful because it saved lives,” says Nick Porter, gift in Moffitt’s history. The center
executive vice president for institutional advancement will allow Moffitt to respond even
and corporate relations. “It also gave us the opportunity more aggressively to Florida’s
to provide cancer education to people throughout the growing melanoma rate and
state, which is one of our mandates.” reduce the state’s burden.
Critical to that outreach was the involvement of
five of Moffitt’s affiliate hospitals, which helped to staff
the events and provided a local link in each community,
particularly those stops outside the Tampa Bay area.
Participants included All Children’s Hospital, St. Joseph’s
Hospital, Martin Memorial Health Systems, Sarasota
Memorial Health Care and Morton Plant Mease Health
Care. “Spring Swing demonstrates that together, with
our affiliate partners around the state, we have tremen-
dous potential to reduce the burden of skin cancer in
the state of Florida,” says Jan Marshburn, administra-
tive director of Strategic Alliances at Moffitt.
Spring Swing began its 1,388-mile trek in
St. Petersburg on March 1 at a game pitting the
Tampa Bay Rays against the Toronto Blue Jays. Sam
Donaldson, a melanoma survivor and chairman of
The Spring SwingTM bus took off across the state and
provided 695 skin cancer screenings. The team
offered information about cancer at each event.
Moffitt Cancer Center 2008 Annual Report
CONSOLIDATED BALANCE SHEET
June 30, 2008 June 30, 2007
Cash & Cash Equivalents $8,050,115 $12,691,966
Current Portion of Assets Limited as to Use 17,706,212 15,161,302
Current Portion of Pledges Receivable 10,912,755 14,786,876
A/R Less Allowance for Uncollectibles 72,089,591 62,933,571
Other Current Assets 26,571,306 21,901,518
Total Current Assets $135,329,979 $127,475,233
Assets Limited as to Use, Net of Current Portion $210,375,498 $110,423,808
Pledges Receivable, Net of Current Portion 6,406,464 9,055,100
Property, Plant & Equipment 275,003,846 269,652,340
Construction in Progress 52,695,252 17,765,631
Other Assets 2,558,765 1,554,638
Total Assets $682,369,804 $535,926,750
LIABILITIES AND NET ASSETS
Current Liabilities $119,376,078 $84,261,820
Other Liabilities 3,363,635 3,569,089
Long-Term Debt, Net of Current Portion 205,192,441 101,333,490
Net Assets 354,437,650 346,762,351
Total Liabilities and Net Assets $682,369,804 $535,926,750
CONSOLIDATED STATEMENT OF REVENUE AND EXPENSES
June 30, 2008 June 30, 2007
Net Patient Service Revenues $406,311,045 $361,256,072
Other Revenues 73,370,620 63,756,926
Net Assets Released from Restrictions
and Used for Operating Expenses 30,005,916 19,306,358
Total Unrestricted Revenue
and Other Support $509,687,581 $444,319,356
Operating Expenses $488,804,976 $415,156,873
Depreciation and Amortization 34,499,509 30,700,610
Interest 4,897,066 4,926,870
Provision for Bad Debts 6,861,028 5,601,699
Total Expenses $535,062,579 $456,386,052
(Loss) Income from Operations $(25,374,998) $(12,066,696)
Non-operating Gains, Net 4,659,495 6,572,257
(Deficiency) Excess of Revenues and
Gains over Expenses and Losses $(20,715,503) $(5,494,439)
2008 PAYER MIX
Andrea Shaffer, R.N., works with Charles Williams, M.D.,
in Moffitt’s Thoracic Oncology Clinic.
10 MOST FREQUENT CANCER SITES: 2007* 2% Private Pay
Bronchus and Lung 10.99% 9.52% Prostate
Skin** 1 1.40% <1% Commercial
Breast 1 1.45%
2.65% Plasma Cell Tumors MOFFITT PATIENT ORIGIN FY 2008
Other Sites 33.50%
12% Pasco County
Other Florida 22%
* Includes analytic and non-analytic cases for accession year 2007
There were a total of 6,880 analytic and non-analytic cases for accession year 2007 10% Pinellas County
** Excludes basal cell and squamous cell carcinoma
Yearly data supplied to Public Relations and Marketing by Cancer Registry for
updating Moffitt Cancer Center’s Annual Report.
5% Polk County
4% Manatee County
County 3% Hernando County
3% Non Florida
2% Sarasota County
ANNUAL TOTALS FY 08 FY 07
Admissions 7,482 7,261
Outpatient Visits 272,532 264,533
Patient Days 47,388 45,377
Average Length of Stay 6.3 days 6.4 days
Xueli Li, M.D., research associate
Moffitt Cancer Center 2008 Annual Report
BOARD OF DIRECTORS BOARD OF ADVISORS
H. Lee Moffitt Cancer Center The Honorable Dick A. Greco Sam Donaldson, Chairman
& Research Institute, Inc. Shay Griese ABC News Correspondent
Robert Rothman, Chair Timm Harmon Clifford L. Alexander, Jr.
Timothy J. Adams, Vice Chair Benjamin H. Hill III, Esquire President, Alexander & Associates, Inc.;
Former Secretary of the Army
Donald D. Buchanan Ken L. Hoverman
The Honorable Carl Carpenter, Jr. Peter T. Kirkwood, Esquire Gary Bettman
Commissioner, National Hockey League
Theodore J. Couch, Sr., Chair Emeritus John Kynes
Celia D. Ferman Steven Matzkin, D.D.S. Francis T. Borkowski, Ph.D.
Former Chancellor, Appalachian State University;
Judy L. Genshaft, Ph.D. Col. John W. Mitchell, Sr. Former President, University of South Florida
The Honorable John A. Grant The Honorable H. Lee Moffitt
The Honorable James T. Hargrett Jim U. Morrison Kimberly Casiano
President, Casiano Communications, Inc.
Monsignor Laurence Higgins Carol Morsani
Benjamin H. Hill III, Esquire Pamela Muma David S. Chernow
Chief Executive Officer, OnCURE Medical Corp.
Beth A. Houghton William F. Poe, Jr.
Rhea F. Law, Esquire Barbara Ryals Robin Cook, M.D.
Physician and Author
Senator Connie Mack, Chair Emeritus Patrick Sobers
The Honorable H. Lee Moffitt Jack Spangler Newt Gingrich
Founder, Center for Health Transformation;
Donald W. Wallace Former Speaker, U.S. House of Representatives
H. Lee Moffitt Cancer Center Julie Wooley
& Research Institute Hospital, Inc. Senator Bob Graham
Former U.S. Senator
Beth A. Houghton, Chair Moffitt Medical Group Former Governor of Florida
The Honorable Mark A. Pizzo, Vice Chair Timothy J. Adams, Chair Bob Griese
W. Michael Alberts, M.D., M.B.A. Rolfe Arnhym College Football Analyst, ABC/ESPN;
Karen A. Arnold Donald D. Buchanan Member, Pro Football Hall of Fame
The Honorable Thomas E. Baynes Jennifer Capeheart-Meningall, Ed.D. Brian Griese
Joseph Caballero Hugo Fernandez, M.D. Tampa Bay Buccaneers Quarterback;
Julie Y. Djeu, Ph.D. Gwen Mitchell Founder & President, Judith Ann Griese Foundation
Manuel Garcia The Honorable H. Lee Moffitt Robert Ingram
Harvey M. Greenberg, M.D., M.B.A. Robert J. Perez, D.D.S. Vice Chairman of Pharmaceuticals, GlaxoSmithKline
Dwayne Hawkins The Honorable Mark A. Pizzo Sidney Kimmel
Ronald A. Hurst Julio M. Pow-Sang, M.D. Founder & Chairman, Jones Apparel Group;
Chairman, Sidney Kimmel Foundation
Stephen K. Klasko, M.D., M.B.A. The Honorable Donald C. Sullivan, M.D.
The Honorable Gwen Miller Richard Klausner, M.D.
Moffitt Technologies Corporation Chairman and Managing Director, The Column Group;
The Honorable H. Lee Moffitt Former Director, National Cancer Institute
Mary Anne Reilly William S. Dalton, Ph.D., M.D., Chair
Janene Culumber, M.S. G. Timothy Laney
George William Tinsley, Sr. Senior Executive Vice President for Business Services,
L. David de la Parte, Esquire Regions Financial Corporation
H. Lee Moffitt Cancer Center John A. Kolosky, C.P.A., M.B.A.
& Research Institute Foundation, Inc. James J. Mulé, Ph.D. Joseph R. Lee
Retired Chairman, Darden Restaurants, Inc.
Edward C. Droste, Chair Nicolas C. Porter, M.Ed.
Alfred S. Austin LaSalle D. Leffall, Jr., M.D.
Charles R. Drew Professor of Surgery,
Suzette M. Berkman M2Gen Howard University College of Medicine
Thilo Best William S. Dalton, Ph.D, M.D., Chair
Donald D. Buchanan Governor Bob Martinez
G. Robert Blanchard, Jr. Senior Policy Adviser, Holland & Knight, LLP;
Joseph Caballero Theodore J. Couch, Sr. Former Governor of Florida
The Honorable Monterey Campbell Kenneth Ford, Ph.D. Former Mayor of Tampa
Ronald J. Campbell Kenneth I. Moch Martin J. Murphy, Jr., Ph.D.
Michael Conroy, C.P.A. The Honorable H. Lee Moffitt Chairman and Chief Executive Officer,
Linda Powers AlphaMed Consulting, Inc.
Joe B. Cox, Esquire
Eileen Sena Curd Robert Rothman Marty Nealon
Daniel M. Sullivan, M.D. Consultant
Rebecca Walter Dunn
Richard Gonzmart Olivia Newton-John
Singer, Songwriter, Actress and Health Advocate
President and CEO, AAA Auto Club South
Professional Golfer and Businessman
Steven A. Raymund
Mary Ann Morgan, Ph.D., A.R.N.P. (left), and Ning Chen, M.D. Chairman of the Board, Tech Data Corporation
ABC News Analyst
H. Norman Schwarzkopf
General, USA, Retired
Chairman of the Board, The Sembler Company;
U.S. Ambassador, Retired
NFL’s Winningest Coach;
Member, Pro Football Hall of Fame;
Chairman, Shula Enterprises, Inc.
Stuart L. Sternberg
Principal Owner, Tampa Bay Rays
President and CEO, Gulf Power Company
Senator Bob Dole
Special Counsel, Alston & Bird;
Former U.S. Senator
President/Chief Executive Officer DIVISION OF BASIC SCIENCES DIVISION OF CLINICAL SCIENCES
& Center Director Scott Antonia, M.D., Ph.D. Claudio Anasetti, M.D.
William S. Dalton, Ph.D., M.D. Co-Program Leader, Immunology Department Chair, Blood & Marrow Transplant
Deputy Center Director Julie Y. Djeu, Ph.D. Lodovico Balducci, M.D.
Department Chair, Immunology Program Leader, Senior Adult Oncology
W. Jack Pledger, Ph.D. Co-Program Leader, Immunology
Gerold Bepler, M.D., Ph.D.
Director, Moffitt Research Institute Robert Gatenby, M.D. Department Chair, Thoracic Oncology
Department Chair, Integrated Mathematical Oncology
Thomas A. Sellers, Ph.D., M.P.H. Claudia G. Berman, M.D.
Saïd Sebti, Ph.D. Service Chief, Radiology
Executive Vice President and Department Chair, Drug Discovery
Program Leader, Drug Discovery
Steven Brem, M.D.
Associate Center Directors Department Chair, Neuro-Oncology
Edward Seto, Ph.D. W. Bradford Carter, M.D.
W. Jack Pledger, Ph.D. Department Chair, Molecular Oncology
Basic Science Program Leader, Endocrine Tumor
Program Leader, Molecular Oncology
Director, National Functional Genomics Center Paul A. Chervenick, M.D.
Thomas A. Sellers, Ph.D., M.P.H. Service Chief, TGH Adult Oncology
Population Sciences DIVISION OF CLINICAL INVESTIGATIONS Domenico Coppola, M.D.
Daniel M. Sullivan, M.D. Department Chair, Anatomic Pathology
Eric Haura, M.D.
Clinical Investigations Program Leader, Experimental Therapeutics Ronald C. DeConti, M.D.
Chief, Medicine Service
Executive Vice Presidents Robert Gatenby, M.D.
David de la Parte DIVISION OF POPULATION SCIENCES Department Chair, Diagnostic Imaging
David Fenstermacher, Ph.D. Richard A. Gross, M.D.
John A. Kolosky, C.P.A., M.B.A. Department Chair, Biomedical Informatics Department Chair, Internal and Hospital Medicine
Chief Operating Officer
Anna Giuliano, Ph.D. Sloan Karver, M.D.
Alan F. List, M.D. Department Chair, Epidemiology and Genetics Program Leader, Psychosocial & Palliative Care
Clinical Sciences Program Leader, Risk Assessment, Detection &
Johnathan M. Lancaster, M.D., Ph.D.
President, Moffitt Medical Group Department Chair, Women’s Oncology
Paul Jacobsen, Ph.D. Christine Laronga, M.D.
James J. Mulé, Ph.D. Department Chair, Health Outcomes & Behavior
Interim Program Leader, Don & Erika Wallace
Applied Science & Technology Program Leader, Health Outcomes & Behavior
Comprehensive Breast Program
Nicolas C. Porter, M.Ed. Director, Total Cancer Care for Health Outcomes
Institutional Advancement and Corporate Relations Michael Schell, Ph.D. G. Douglas Letson, M.D.
Department Chair, Sarcoma
Timothy J. Yeatman, M.D. Department Chair, Biostatistics
Associate Chair, Graduate Medical Education
President & Chief Scientific Officer, M2Gen Mokenge P. Malafa, M.D.
Director, Total Cancer Care for Personalized Medicine COMPREHENSIVE RESEARCH CENTERS Department Chair, Gastrointestinal Oncology
Director, Comprehensive Lung Cancer Thomas V. McCaffrey, M.D., Ph.D.
Senior Vice President Research Center
Program Leader, Head & Neck Oncology
Braulio Vicente, Jr., M.B.A. Gerold Bepler, M.D., Ph.D. Lynn C. Moscinski, M.D.
Chief Operating Officer, Hospital/Clinics Department Chair, Hematopathology and
Director, Comprehensive Drug Discovery Laboratory Medicine
Vice Presidents Research Center Chief Academic Officer
Chair, USF Department of Oncology Sciences
W. Michael Alberts, M.D., M.B.A. Saïd Sebti, Ph.D.
Medical Affairs/Chief Medical Officer Julio M. Pow-Sang, M.D.
Director, Donald A. Adam Comprehensive Department Chair, Genitourinary Oncology
Michael Benedict, Pharm.D. Melanoma Research Center Service Chief, Surgery
Jeffrey S. Weber, M.D., Ph.D. Vernon Sondak, M.D.
Janene Culumber, M.S. Department Chair, Cutaneous Oncology
Chief Financial Officer
Eduardo Sotomayor, M.D.
Larry Feder Department Chair, Malignant Hematology
Craig W. Stevens, M.D., Ph.D.
Anne Goff, M.Ed. Department Chair, Radiation Oncology
Research Operations/CCSG Administrator Service Chief, Radiation Oncology
Brenda Gordon, R.N., M.S.N., O.C.N. David Thrush, M.D.
Ancillary Services Department Chair, Anesthesiology
B. Lee Green, Ph.D. Service Chief, Anesthesiology
Kelly Hall, M.B.A. MEDICAL STAFF OFFICERS
Moffitt Medical Group Operations
Dean Head Larry K. Kvols, M.D.
Facilities Management & Construction President
Mary Beth Reardon, R.N., M.S. Barbara A. Centeno, M.D.
Patient Care Services/Chief Nursing Officer President-Elect
Yvette Tremonti Sophie Dessureault, M.D., Ph.D.
Human Resources Secretary/Treasurer
Jamie Wilson Melissa Alsina, M.D.
Government Relations Member-At-Large
Christine Laronga, M.D.
Wade J. Sexton, M.D.
Margaret M. Szabunio, M.D.
CH-4675. NO PERCENTAGE OF CONTRIBUTIONS ARE RETAINED BY A PROFESSIONAL SOLICITOR, 100% OF ALL DONATIONS ARE RECEIVED BY THE FOUNDATION.
SERVICES BY CALLING 1-800-435-7352 TOLL
FLORIDA IS THE OFFICIAL PLACE OF BUSINESS FOR THE H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE FOUNDATION, INC. A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, AN NCI COMPREHENSIVE CANCER CENTER – TAMPA, FL.
Third Miles For Moffitt
Tampa, FL 33612-9416
12902 Magnolia Drive
& Research Institute Inc
H. Lee Moffitt Cancer Center
like to be removed from the mailing list, please call 813-745-1355.
Additional copies may be obtained by calling 813-745-1355. If you would
Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612-9416.
Institute is published by the Department of Public Relations & Marketing,
This 2008 annual report for the H. Lee Moffitt Cancer Center & Research
Photography: Dick Dickinson
Design: JAG Communications, Inc.
Contributing Writers: Cathy Clark, Randolph Fillmore
Managing Editor: Cathy Clark
Director, Marketing & Strategic Communications: Melissa Mackey
Race Reaches Record
More than 3,000 runners
and walkers made the 2008
Miles for Moffitt a landmark
morning for cancer research
at Moffitt Cancer Center last
spring. The 5K race/fitness
-FREE WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE. FLORIDA DEPARTMENT OF AGRICULTURE & CONSUMER SERVICES REGISTRATION NUMBER
walk and one mile fun run/walk, held May 10 at
the University of South Florida (USF) Sun Dome,
far exceeded the previous
year’s participation of 2,400.
The third annual race
event, which benefits cancer
research programs at Moffitt,
culminated with a celebration
where cancer survivors who
participated in the race were
“The cancer survivors are the real inspiration
for this event,” says Karen Dalton, Miles for Moffitt
founder and wife of William S. Dalton, Ph.D., M.D.,
Moffitt president and CEO. Mrs. Dalton has a
very active and committed board that includes
Sponsorship Chair Priscilla Mack, wife of Senator
Connie Mack, Moffitt Board chair emeritus.
“Cancer research is the key to survivorship,
and this race helps Moffitt’s researchers continue
to make milestones toward the prevention,
treatment and cure of cancer,” says Mrs. Dalton.
Since its beginning in 2006, Miles for Moffitt has
raised a total of $230,000 for Moffitt’s research
programs. “Sponsor underwriting of the race
allows 100 percent of the proceeds to go directly
to cancer research,” says Mrs. Dalton. “So far
Miles for Moffitt has allowed us to give five awards
to junior faculty who are working to learn more
about cancer and how it can be cured.” Proceeds
from the 2008 race will be awarded at Moffitt’s
Scientific Research Meeting in February 2009.
“Cancer research is
the key to survivorship...”
Visit www.MilesForMoffitt.com for more race
details, and be sure to save the date — Saturday,
May 9, 2009 — for the Florida Bank Miles for
PERMIT NO 2849